Dynamic Contrast Enhanced Magnetic Resonance Imaging Evaluates Therapeutic Mechanism of nab-Paclitaxel in Pancreatic Cancer Patient Derived Xenograft Mouse Models.
Hyunki Kim 1 , Sharon Samuel 1 , Marie Warren 1 , Guihua Zhai 1 , William Grizzle 1 , Denise Oelschlager 1 , Pedro Lopez-Casas 2 , Manuel Hidalgo 2 , Joy Kovar 3 , Kurt Zinn 1 , and Donald Buchsbaum 1
University of Alabama at Birmingham,
Birmingham, AL, United States,
National Cancer Research Center, Madrid, Spain,
Biosciences, Nebraska, United States
Dynamic contrast enhanced magnetic resonance imaging
(DCE-MRI) was employed to identify the therapeutic
mechanism of nab-paclitaxel in pancreatic cancer patient
derived xenograft mouse models. DCE-MRI demonstrated
that nab-paclitaxel did not significantly increase the
microvascular perfusion in tumor xenografts for 3 weeks
of nab-paclitaxel treatment, although gemcitabine did.
Also, histologic analysis showed that tumor stroma was
not significantly reduced by nab-paclitaxel, but high
tumor retention of fluorophore labeled nab-paclitaxel
was observed. Therefore the significant clinical
benefits of nab-paclitaxel may result from its effective
delivery into tumors in pancreatic cancer.
This abstract and the presentation materials are available to members only;
a login is required.